MA provision by pharmacy workers: Scale, quality and strategies to improve provision practices

Katy Footman, Marie Stopes International
Background

- Pharmacies are often a first, preferred source of health care due to convenience, privacy, anonymity, low costs.

- Very little data available but what we have suggests MA purchased from pharmacies is growing trend.

- Potential to reduce morbidity and mortality associated with unsafe abortion.

- But women need adequate information and counselling to be able to use MA drugs effectively.

<table>
<thead>
<tr>
<th>Role of self-management approaches</th>
<th>Self</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical abortion in the first trimester</td>
<td>No recommendation for overall task – recommendations for specific components as below</td>
</tr>
<tr>
<td>Self-assessing eligibility</td>
<td></td>
</tr>
<tr>
<td>Managing the mifepristone and misoprostol medication without direct supervision of a health-care provider</td>
<td></td>
</tr>
<tr>
<td>Self-assessing completeness of the abortion process</td>
<td></td>
</tr>
<tr>
<td>Self-administering injectable contraception</td>
<td></td>
</tr>
</tbody>
</table>
Systematic review methods

**Aims:** to describe the scale and practice of pharmacy provision of MA; to assess the effectiveness of interventions aiming to improve the scale and/or quality

**Timeline:** November 2015

**Databases:** MEDLINE, Web of Science, POPLINE, Embase, Global Health and WHO Reproductive Health Library. Hand-searching websites of six organisations involved in MA research and provision in LMICs. Snowballing on references.

**Search terms:** range of terms related to abortion + range of terms related to pharmacies, drug sellers, or self-medication were used.

**Inclusion criteria:** outcomes met the review objectives; study design used quantitative primary data collection methods; published between 1st January 1990 and 1st October 2015; in English, Spanish or French language; LMIC setting; published peer-reviewed journal articles and grey literature.

**Data extraction:** double-extracted using standardised template.

**Quality assessment:** double graded using standardised checklist
Search results

Citations identified in database search (N=2989)

Title and abstract screening

Full text evaluated (N=61)

Excluded (N=2932):
Duplicates, non LMICs, not related to medical abortion

Studies identified through database search (N=21)

Excluded (N=40)
Not related to pharmacy provision of MA (N=18)
Sample of women visiting hospital for PAC (N=7)
Not primary data (N=3)
Not related to MA (other aspects of reproductive health) (N=3)
Intervention study with no baseline data to extract (N=2)
Language (N=1)
Qualitative studies (N=6)

Studies identified through hand-searching and contacts with experts (N=4)

Studies included in the review (N=25)
Where has research been conducted?

- 2 or 3 high quality studies
- 2 medium-high quality studies
- 2 medium-low quality studies
- 1 medium-high quality study
- 1 medium-low quality studies
- 1 low quality study
- No studies
Availability of MA

• Globally, provision of abortifacients by pharmacies was common without prescription.

• Considerable variation by setting and over time.

• Mifepristone less widely available

• Ineffective abortifacients also commonly provided.

• Variation also by methodology used.

• Pharmacies reported demand for MA was common.

Bars show % pharmacies offering misoprostol-only.
*Survey, ^Mystery client
Knowledge and counselling

• Knowledge of, or counselling on, an effective regimen for the drug most commonly sold is rare.

• Knowledge of the correct regimen did not always translate into accurate advice to mystery clients.

• Mystery clients rarely advised on what to do in case of complications.

• Referrals not commonly offered.

<table>
<thead>
<tr>
<th>Country</th>
<th>Year</th>
<th>Nature of intervention</th>
<th>Nature of evaluation</th>
<th>Result: intervention successful?</th>
<th>Overall quality grade</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zambia 2015</td>
<td>One day training</td>
<td>Pre-post, no comparison</td>
<td>Increase in referrals (47%-68%)</td>
<td>Low</td>
<td></td>
</tr>
<tr>
<td>Bangladesh 2015</td>
<td>Training, in-pharmacy detailing &amp; call centre</td>
<td>Post-intervention survey, comparison with control group</td>
<td>Increased odds of knowing correct miso-regimen among miso-sellers if: used call centre (aOR 2.01); received training (aOR 1.89); received detailing (aOR 1.73).</td>
<td>Medium</td>
<td></td>
</tr>
<tr>
<td>Nepal 2015</td>
<td>Two day training + 1 day refresher course 10 months later.</td>
<td>Pre-post, comparison group in different region</td>
<td>Improvement in: knowledge of regimen (22% to 88% (I) vs 23% to 41% (C)) identifying complete abortion in intervention group (65% to 77% (I), 51% to 49% (C)).</td>
<td>Medium</td>
<td></td>
</tr>
</tbody>
</table>
Conclusions

Research on MA availability in pharmacies is needed

Provision appears to be widespread, but often with poor knowledge and provision of information

Providing training and information can improve knowledge and practice

More evidence is needed on what works for improving quality of MA provision and safety of self-administration

But how?
MSI pilot to assess client outcomes after self-managed MA

- Pharmacy workers recruit client into study using standardised script & voucher.
- Pharmacy workers reimbursed USD 12.70, women reimbursed USD 1.15.
- Client instructed to send an SMS with voucher ID to call center
- Immediate phone back from call center & follow up interview arranged
- Follow up phone interview after 2 weeks

- Most pharmacies willing to take part but low continuing commitment.
- Majority of clients were recruited from a small number of pharmacies
- Initial enrolment was main barrier to representative sample:
  Overall response rate = 30%
  Follow up rate = 87%
- Final sample: 109
- Other challenges: self-reported outcomes
Next steps:

Lessons learned:
• Pharmacy staff reimbursement important but more monitoring needed
• Immediate contact by phone facilitated recruitment
• Inclusion of all pharmacy staff needed

Future attempts needed:
– In settings where misoprostol-only is commonly provided
– With measures to improve recruitment process – more convenient, less potentially threatening
– Ongoing reimbursement of pharmacy staff rather than one-off payment?
– Expanding number of pharmacies to increase client numbers
– Investing in hiring research assistants to be based in pharmacy
– Alternatives - recruitment of women accessing hotlines/call centres
– Validation of measures of self-reported complications/outcomes also needed.
Thank you